OTCMKTS:DNPUF Sumitomo Pharma (DNPUF) Stock Price, News & Analysis $11.91 0.00 (0.00%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Sumitomo Pharma Stock (OTCMKTS:DNPUF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sumitomo Pharma alerts:Sign Up Key Stats Today's Range$11.91▼$11.9150-Day Range$9.27▼$14.2152-Week Range$8.41▼$19.20VolumeN/AAverage Volume1,303 shsMarket CapitalizationN/AP/E Ratio0.20Dividend Yield120.63%Price TargetN/AConsensus RatingN/A Company Overview Sumitomo Pharma Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacture and commercialization of prescription medicines. Its portfolio and development activities have focused on psychiatric and neurological disorders, oncology, gynecological health and other areas of significant unmet medical need. The company also conducts research in regenerative medicine and cell therapy. The company has marketed medicines including Latuda (lurasidone), an antipsychotic used in the treatment of schizophrenia and bipolar depression, as well as products for conditions such as overactive bladder and other specialized therapeutic areas. Its products and research programs have supported operations in Japan and international markets, including the United States and other regions. Sumitomo Pharma was formed in 2005 through the merger of Dainippon Pharmaceutical and Sumitomo Pharmaceuticals and was previously known as Sumitomo Dainippon Pharma. The company adopted the Sumitomo Pharma name in 2022. It is headquartered in Osaka, Japan, and operates as part of the broader Sumitomo group of companies.AI Generated. May Contain Errors. Read More Sumitomo Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreDNPUF MarketRank™: 0.19541149793 of 5 starsSumitomo Pharma scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Sumitomo Pharma. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sumitomo Pharma is 0.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Sumitomo Pharma is 0.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.Read more about Sumitomo Pharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverSumitomo Pharma has a short interest ratio ("days to cover") of 78.2, which indicates bearish sentiment.Change versus previous monthShort interest in Sumitomo Pharma has recently increased by 50.49%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldSumitomo Pharma pays a meaningful dividend of 1.27%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSumitomo Pharma does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Sumitomo Pharma is 24.70%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Sumitomo Pharma's dividend. News and Social Media0.6 / 5News SentimentN/A News SentimentSumitomo Pharma has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sumitomo Pharma this week, compared to 0 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sumitomo Pharma insiders have not sold or bought any company stock.Percentage Held by Institutions7.58% of the stock of Sumitomo Pharma is held by institutions.Read more about Sumitomo Pharma's insider trading history. Receive DNPUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sumitomo Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNPUF Stock News HeadlinesSumitomo Pharma Rejects Short-Seller Allegations, Stands by Audited AccountsAugust 4, 2026 | tipranks.comNew Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPHMay 18, 2026 | businesswire.comPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.November 17 at 1:00 AM | OilPrice (Ad)Sumitomo Pharma Co., Ltd. GAAP EPS of ¥268.99, revenue of ¥453.29BMay 13, 2026 | seekingalpha.comSumitomo Pharma Profit Jumps on U.S. Asset Transfer and Asian Stake SaleMay 12, 2026 | tipranks.comSumitomo Pharma Launches Major Share Offering to Strengthen Financial BaseApril 8, 2026 | tipranks.comSumitomo Pharma to Book ¥48.3 Billion Dividend as Non-Operating Income With No Group Profit ImpactMarch 25, 2026 | tipranks.comSumitomo Pharma shares plunge nearly 16% despite greenlight for Parkinson's treatmentFebruary 20, 2026 | cnbc.comSee More Headlines DNPUF Stock Analysis - Frequently Asked Questions How have DNPUF shares performed this year? Sumitomo Pharma's stock was trading at $14.36 at the beginning of 2026. Since then, DNPUF stock has decreased by 17.0% and is now trading at $11.9135. How do I buy shares of Sumitomo Pharma? Shares of DNPUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/16/2026Next Earnings (Estimated)1/29/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:DNPUF CIKN/A Webwww.sumitomo-pharma.com Phone81 6 6203 5321FaxN/AEmployees3,123Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.20 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:DNPUF) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sumitomo Pharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sumitomo Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.